Venous and arterial thrombotic risks with thalidomide: Evidence and practical guidance

Therapeutic Advances in Drug Safety

Volumn 3, Issue 5, 2012, Pages 255-266

  Palumbo, Antonio ^a   Palladino, Carmela ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

aspirin; heparin; multiple myeloma; novel agents; thalidomide; thromboprophylaxis; venous thromboembolism; warfarin

Indexed keywords

ACETYLSALICYLIC ACID; BORTEZOMIB; CYCLOPHOSPHAMIDE; DABIGATRAN ETEXILATE; DALTEPARIN; DEXAMETHASONE; DOXORUBICIN; ENOXAPARIN; HEPARIN; MELPHALAN; PREDNISONE; RIVAROXABAN; THALIDOMIDE; WARFARIN;

ARTERIAL THROMBOEMBOLISM; BLEEDING; CANCER RISK; CARDIOVASCULAR RISK; DRUG EFFICACY; HISTORY OF MEDICINE; HUMAN; IMMUNOMODULATION; MULTIPLE MYELOMA; PHASE 2 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; TREATMENT RESPONSE; VENOUS THROMBOEMBOLISM;

EID: 84868653802     PISSN: 20420986     EISSN: 20420994     Source Type: Journal    
DOI: 10.1177/2042098612452291     Document Type: Review

References (77)

1. Ageno W. Squizzato A. Garcia D. Imberti D. (2006) Epidemiology and risk factors of venous thromboembolism. Semin Thromb Hemost 32: 651–658.
2. Anaissie E. Coleman E. Goodwin J. Kennedy R. Lockhart K. Stewart C. (2012) Prophylactic recombinant erythropoietin therapy and thalidomide are predictors of venous thromboembolism in patients with multiple myeloma: limited effectiveness of thromboprophylaxis. Cancer 118: 549–557.
3. Anderson K. (2005) Lenalidomide and thalidomide: mechanisms of action–similarities and differences. Semin Hematol 42(4 Suppl. 4): S3–S8.
4. Ansell J. Hirsh J. Hylek E. Jacobson A. Crowther M. Palareti G. (2008) Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence- Based Clinical Practice Guidelines (8th Edition). Chest 133: 160S–198S.
5. Barlogie B. Desikan R. Eddlemon P. Spencer T. Zeldis J. Munshi N. (2001) Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood 98: 492–494.
6. Barlogie B. Tricot G. Anaissie E. Shaughnessy J. Rasmussen E. van Rhee F. (2006) Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med 354: 1021–1030.
7. Bassand J. Hamm C. Ardissino D. Boersma E. Budaj A. Fernández-Avilés F. (2007) Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J 28: 1598–1660.
8. Bauer K. (2001) The thrombophilias: well-defined risk factors with uncertain therapeutic implications. Ann Intern Med 135: 367–373.
9. Baz R. Li L. Kottke-Marchant K. Srkalovic G. McGowan B. Yiannaki E. (2005) The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma. Mayo Clin Proc 80: 1568–1574
10. Beksac M. Haznedar R. Firatli-Tuglular T. Ozdogu H. Aydogdu I. Konuk N. (2011) Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group. Eur J Haematol 86: 16–22.
11. Bick R. (2003) Cancer-associated thrombosis. N Engl J Med 349: 109–111.
12. Blom J. Doggen C. Osanto S. Rosendaal F. (2005) Malignancy, prothrombotic mutations, and the risk of venous thrombosis. JAMA 293: 715–722.
13. Buller H. Davidson B. Decousus H. Gallus A. Gent M. Piovella F. (2003) Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med 349: 1695–1702.
14. Buller H. Davidson B. Decousus H. Gallus A. Gent M. Piovella F. (2004) Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: A randomized trial. Ann Intern Med 140: 867–873.
15. Cohen A. Skinner J. Kakkar V. (1994) Antiplatelet treatment for thromboprophylaxis: a step forward or backwards? BMJ 309: 1213–1215.
16. Corso A. Lorenzi A. Terulla V. Airò F. Varettoni M. Mangiacavalli S. (2004) Modification of thrombomodulin plasma levels in refractory myeloma patients during treatment with thalidomide and dexamethasone. Ann Hematol 83: 588–591.
17. Dimopoulos M. Anagnostopoulos A. Terpos E. Repoussis P. Zomas A. Katodritou E. (2006) Primary treatment with pulsed melphalan, dexamethasone and thalidomide for elderly symptomatic patients with multiple myeloma. Haematologica 91: 252–254.
18. Dimopoulos M. Anagnostopoulos A. Weber D. (2003) Treatment of plasma cell dyscrasias with thalidomide and its derivates. J Clin Oncol 21: 4444–4454.
19. Dimopoulos M. Hamilos G. Zomas A. Gika D. Efstathiou E. Grigoraki V. (2004) Pulsed cyclophosphamide, thalidomide and dexamethasone: an oral regimen for previously treated patients with multiple myeloma. Hematol J 5: 112–117.
20. Dimopoulos M.A. Kastritis E. Rosinol L. Bladé J. Ludwig H. (2008) Pathogenesis and treatment of renal failure in multiple myeloma. Leukemia 22: 1485–1493.
21. Eby C. Blinder M. (2003) Hemostatic complications associated with paraproteinemias. Curr Hematol Rep 2: 388–394.
22. Facon T. Mary J. Hulin C. Benboubker L. Attal M. Pegourie B. (2007) Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet 370: 1209–1218.
23. FDA (2010) Questions and Answers on Medication Guides for Erythropoiesis-Stimulating Agents (ESAs). Accessed 12 December 2011, at http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm109380.htm.
24. Fox E. Kahn S. (2005) The relationship between inflammation and venous thrombosis. A systematic review of clinical studies. Thromb Haemost 94: 362–365.
25. Friedman R. (2009) New oral anticoagulants for thromboprophylaxis after total hip or knee arthroplasty. Orthopedics 32: 79–84.
26. Fuster V. Moreno P. Fayad Z. Corti R. Badimon J. (2005) Atherothrombosis and high-risk plaque: part I: evolving concepts. J Am Coll Cardiol 46: 937–954.
27. García-Sanz R. González-Porras J. Hernández J. Polo-Zarzuela M. Sureda A. Barrenetxea C. (2004) The oral combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is effective in relapsed/refractory multiple myeloma. Leukemia 18: 856–63.
28. Heit J. O–Fallon W. Petterson T. Lohse C. Silverstein M. Mohr D. (2002) Relative impact of risk factors for deep vein thrombosis and pulmonary embolism. Arch Intern Med 162: 1245–1248.
29. Heit J. Silverstein M. Mohr D. Petterson T. O–Fallon W. Melton L. (1999) Predictors of survival after deep vein thrombosis and pulmonary embolism: a population-based cohort study. Arch Intern Med 159: 445–453.
30. Heit J. Silverstein M. Mohr D. Petterson T. O–Fallon W. Melton L. (2000) Risk factors for deep vein thrombosis and pulmonary embolism. Arch Intern Med 160: 809–815.
31. Hovenga S. Daenen S. de Wolf J. van Imhoff G. Kluin-Nelemans H. Sluiter W. (2005) Combined thalidomide and cyclophosphamide treatment for refractory or relapsed multiple myeloma patients: a prospective phase II study. Ann Hematol 84: 311–316.
32. Hovens M. Snoep J. Tamsma J. Huisman M. (2006) Aspirin in the prevention and treatment of venous thromboembolism. J Thromb Haemost 4: 1470–1475.
33. Hulin C. Facon T. Rodon P. Pegourie B. Benboubker L. Doyen C. (2009) Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial. J Clin Oncol 27: 3664–3670.
34. Kaushal V. Kaushal G. Melkaveri S. Mehta P. (2004) Thalidomide protects endothelial cells from doxorubicin-induced apoptosis but alters cell morphology. J Thromb Haemost 2: 327–334.
35. Kristinsson S. (2010) Thrombosis in multiple myeloma. Hematology Am Soc Hematol Educ Program 2010: 437–444.
36. Kropff M. Lang N. Bisping G. Dominé N. Innig G. Hentrich M. (2003) Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in primary refractory or relapsed multiple myeloma. Br J Haematol 122: 607–616.
37. Kumar S. Gertz M. Dispenzieri A. Lacy M. Geyer S. Iturria N. (2003) Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myeloma. Mayo Clin Proc 78: 34–39.
38. Kyriakou C. Thomson K. D–Sa S. Flory A. Hanslip J. Goldstone A. (2005) Low-dose thalidomide in combination with oral weekly cyclophosphamide and pulsed dexamethasone is a well tolerated and effective regimen in patients with relapsed and refractory multiple myeloma. Br J Haematol 129: 763–770.
39. Lacy M. (2010) Arterial thrombosis complicates myeloma. Blood 116: 2–3.
40. Landefeld C. Beyth R. (1993) Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention. Am J Med 95: 315–328.
41. Lloyd-Jones D. Adams R. Brown T. Carnethon M. Dai S. De Simone G. (2010) Heart disease and stroke statistics–2010 update: a report from the American Heart Association. Circulation 121: e46–e215.
42. Lyman G.H. Khorana A.A. Falanga A. Clarke-Pearson D. Flowers C. Jahanzeb M. (2007) American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 25: 5490–5505.
43. Neben K. Moehler T. Benner A. Kraemer A. Egerer G. Ho A. (2002) Dose-dependent effect of thalidomide on overall survival in relapsed multiple myeloma. Clin Cancer Res 8: 3377–3382.
44. Niesvizky R. Badros A. (2010) Complications of multiple myeloma therapy, part 2: risk reduction and management of venous thromboembolism, osteonecrosis of the jaw, renal complications, and anemia. J Natl Compr Canc Netw 8: S13–S20.
45. Niesvizky R. Martínez-Baños D. Jalbrzikowski J. Christos P. Furst J. De Sancho M. (2007) Prophylactic low-dose aspirin is effective antithrombotic therapy for combination treatments of thalidomide or lenalidomide in myeloma. Leuk Lymphoma 48: 2330–2337.
46. Osman K. Comenzo R. Rajkumar S. (2001) Deep venous thrombosis and thalidomide therapy for multiple myeloma. N Engl J Med 344: 1951–1952.
47. Palumbo A. Bringhen S. Caravita T. Merla E. Capparella V. Callea V. (2006) Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 367: 825–831.
48. Palumbo A. Bringhen S. Rossi D. Cavalli M. Larocca A. Ria R. (2010) Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial. J Clin Oncol 28: 5101–5109.
49. Palumbo A. Cavo M. Bringhen S. Zamagni E. Romano A. Patriarca F. (2011) Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial. J Clin Oncol 29: 986–993.
50. Palumbo A. Facon T. Sonneveld P. Bladè J. Offidani M. Gay F. (2008a) Thalidomide for treatment of multiple myeloma: 10 years later. Blood 111: 3968–3977.
51. Palumbo A. Rajkumar S. Dimopoulos M. Richardson P. San Miguel J. Barlogie B. (2008b) Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia 22: 414–423.
52. Prandoni P. Falanga A. Piccioli A. (2005) Cancer and venous thromboembolism. Lancet Oncol 6: 401–410.
53. Pulmonary Embolism Prevention (PEP) Trial Collaborative Group (2000) Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial. Lancet 355: 1295–1302.
54. Rajkumar S. Blood E. Vesole D. Fonseca R. Greipp P. (2006) Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: A clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 24: 431–436.
55. Rajkumar S. Gertz M. Lacy M. Dispenzieri A. Fonseca R. Geyer S. (2003) Thalidomide as initial therapy for early-stage myeloma. Leukemia 17: 775–779.
56. Rosamond W. Flegal K. Furie K. Go A. Greenlund K. Haase N. (2008) Heart disease and stroke statistics - 2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 117: e25–e146.
57. Samama M. (2000) An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients: the Sirius study. Arch Intern Med 160: 3415–3420.
58. Scarpace S. Hahn T. Roy H. Brown K. Paplham P. Chanan-Khan A. (2005) Arterial thrombosis in four patients treated with thalidomide. Leuk Lymphoma 46: 239–242.
59. Sidra G. Williams C. Russell N. Zaman S. Myers B. Byrne J. (2006) Combination chemotherapy with cyclophosphamide, thalidomide and dexamethasone for patients with refractory, newly diagnosed or relapsed myeloma. Haematologica 91: 862–863.
60. Silverstein M. Heit J. Mohr D. Petterson T. O–Fallon W. Melton L. (1998) Trends in the incidence of deep vein thrombosis and pulmonary embolism. A 25-year population-based study. Arch Intern Med 158: 585–593.
61. Snowden J.A. Ahmedzai S.H. Ashcroft J. D–Sa S. Littlewood T. Low E. (2011) Guidelines for supportive care in multiple myeloma 2011. Br J Haematol 154: 76–103.
62. Srkalovic G. Cameron M. Rybicki L. Deitcher S. Kattke-Marchant K. Hussein M. (2004) Monoclonal gammopathy of undetermined significance and multiple myeloma are associated with an increased incidence of venothromboembolic disease. Cancer 101: 558–566.
63. Streetly M. Hunt B. Parmar K. Jones R. Zeldis J. Schey S. (2005) Markers of endothelial and haemostatic function in the treatment of relapsed myeloma with the immunomodulatory agent Actimid (CC-4047) and their relationship with venous thrombosis. Eur J Haematol 74: 293–296.
64. Teo S. (2005) Properties of thalidomide and its analogues: implications for anticancer therapy. AAPS J 7: E14–E19.
65. Thomas D. Kantarjian H. (2001) The revitalization of thalidomide. Ann Oncol 12: 885–886.
66. Tseng S. Pak G. Washenik K. Pomeranz M. Shupack J. (1996) Rediscovering thalidomide: a review of its mechanism of action, side effects, and potential uses. J Am Acad Dermatol 35: 969–979.
67. Vidal-Vanaclocha F. Fantuzzi G. Mendoza L. Fuentes A. Anasagasti M. Martín J. (2000) IL-18 regulates IL-1beta-dependent hepatic melanoma metastasis via vascular cell adhesion molecule-1. Proc Natl Acad Sci U S A 97: 734–739.
68. Waage A. Gimsing P. Fayers P. Abildgaard N. Ahlberg L. Björkstrand B. (2010) Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma. Blood 116: 1405–1412.
69. Weber D. (2003) Thalidomide and its derivatives: new promise for multiple myeloma. Cancer Control 10: 375–83.
70. Weber D. Rankin K. Gavino M. Delasalle K. Alexanian R. (2003) Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 21: 16–19.
71. White R. Zhou H. Romano P. (2003) Incidence of symptomatic venous thromboembolism after different elective or urgent surgical procedures. Thromb Haemost 90: 446–455.
72. Wijermans P. Schaafsma M. Termorshuizen F. Ammerlaan R. Wittebol S. Sinnige H. (2010) Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study. J Clin Oncol 28: 3160–3166.
73. Yakoub-Agha I. Attal M. Dumontet C. Delannoy V. Moreau P. Berthou C. (2002) Thalidomide in patients with advanced multiple myeloma: a study of 83 patients – report of the Intergroupe Francophone du Myelome (IFM). Hematol J 3: 185–192.
74. Zangari M. Barlogie B. Anaissie E. Saghafifar F. Eddlemon P. Jacobson J. (2004) Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation. Br J Haematol 126: 715–721.
75. Zangari M. Elice F. Fink L. Tricot G. (2007) Thrombosis in multiple myeloma. Expert Rev Anticancer Ther 7: 307–315.
76. Zangari M. Saghafifar F. Mehta P. Barlogie B. Fink L. Tricot G. (2003) The blood coagulation mechanism in multiple myeloma. Semin Thromb Hemost 29: 275–282.
77. Zonder J. (2006) Thrombotic complications of myeloma therapy. Hematology Am Soc Hematol Educ Program: 348–355.